Sarah Parish

• The Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin with Laropiprant on Health and Healthcare Costs

  Journal article

  Mihaylova BN. et al, (2016), Circulation: Cardiovascular Quality and Outcomes

• Lipoprotein-Associated Phospholipase A2 Loss-of-Function Variant and Risk of Vascular Diseases in 90,000 Chinese Adults.

  Journal article

  Millwood IY. et al, (2016), J Am Coll Cardiol, 67, 230 - 231

• Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation.

  Journal article

  Kato N. et al, (2015), Nat Genet, 47, 1282 - 1293

• Carotid artery stenosis, cardiovascular risk factors and ischaemic stroke in the China Kadoorie Biobank Study

  Conference paper

  Parish S. et al, (2015), EUROPEAN HEART JOURNAL, 36, 90 - 90

• Hypertension and age-specific burden of carotid atherosclerosis in China: results from 25,000 individuals in the China Kadoorie biobank study

  Conference paper

  Clarke R. et al, (2015), EUROPEAN HEART JOURNAL, 36, 993 - 993

• Cognitive aging and the incidence of cardiovascular events and diabetes: a meta-analysis of the HPS, SEARCH and HPS2-THRIVE studies

  Conference paper

  Parish S. et al, (2015), EUROPEAN HEART JOURNAL, 36, 981 - 981

• Reply to Garrard and Jacoby and Smith et al.

  Journal article

  Clarke R. et al, (2015), Am J Clin Nutr, 101, 416 - 417

• Mthfr c677t genotype is not associated with ischaemic heart disease and stroke in a large prospective study in china

  Conference paper

  Bennett D. et al, (2014), EUROPEAN HEART JOURNAL, 35, 52 - 52

• Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease.

  Journal article

  Hopewell JC. et al, (2014), J Intern Med, 276, 260 - 268

• Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals.

  Journal article

  Clarke R. et al, (2014), Am J Clin Nutr, 100, 657 - 666

• Effects of extended-release niacin with laropiprant in high-risk patients.

  Journal article

  HPS2-THRIVE Collaborative Group None. et al, (2014), N Engl J Med, 371, 203 - 212

• Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease

  Journal article

  Hopewell JC. et al, (2014), Journal of Internal Medicine, 276, 260 - 268

• A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.

  Journal article

  Mangravite LM. et al, (2013), Nature, 502, 377 - 380

• Reply: To PMID 22334567.

  Journal article

  Antoniades CG. and Wendon J., (2013), Hepatology, 58, 1187 - 1188

• HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

  Journal article

  HPS2-THRIVE Collaborative Group None., (2013), Eur Heart J, 34, 1279 - 1291

• Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.

  Journal article

  Hopewell JC. et al, (2013), Eur Heart J, 34, 982 - 992

• The Impact of Genetic Variants Related to LDL-cholesterol on Risk of Ischemic Stroke and Coronary Heart Disease

  Journal article

  Hopewell JC. et al, (2012), CIRCULATION, 126

• Environmental and genetic risk factors for myopathy in Chinese participants from HPS2-THRIVE

  Conference paper

  Hopewell JC. et al, (2012), EUROPEAN HEART JOURNAL, 33, 445 - 445

• Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.

  Journal article

  Parish S. et al, (2012), Circulation, 125, 2469 - 2478

• Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias.

  Journal article

  Clarke R. et al, (2012), PLoS Med, 9

• Large-scale association analysis identifies new risk loci for coronary artery disease

  Journal article

  Deloukas P. et al, (2012), Nature Genetics

• Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.

  Journal article

  Heart Protection Study Collaborative Group None., (2011), Lancet, 378, 2013 - 2020

• Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes.

  Journal article

  Strawbridge RJ. et al, (2011), Diabetes, 60, 2624 - 2634

• Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study

  Journal article

  Hopewell JC. et al, (2011), EUROPEAN HEART JOURNAL, 32, 154 - 155

• The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

  Journal article

  Baigent C. et al, (2011), Lancet, 377, 2181 - 2192

• C-reactive protein in the Heart Protection Study - Authors' reply

  Journal article

  Emberson J. et al, (2011), The Lancet, 377, 1918 - 1919

• No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.

  Journal article

  Hopewell JC. et al, (2011), J Am Coll Cardiol, 57, 2000 - 2007

• A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease.

  Journal article

  Coronary Artery Disease (C4D) Genetics Consortium None., (2011), Nat Genet, 43, 339 - 344

• C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study

  Journal article

  Emberson J. et al, (2011), Lancet, 377, 469 - 476

• Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.

  Journal article

  Hopewell JC. et al, (2011), Circ Cardiovasc Genet, 4, 68 - 73

• Lipoprotein(a) Genetic Variants Associated With Risk of Atherothrombotic Disease in 14,465 Participants From the Heart Protection Study

  Journal article

  Hopewell JC. et al, (2010), CIRCULATION, 122

• A Genome-Wide Association Study of Risk of Coronary Artery Disease in European and South Asian Populations

  Journal article

  Hopewell JC. et al, (2010), CIRCULATION, 122

• Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.

  Journal article

  Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group None. et al, (2010), Lancet, 376, 1658 - 1669

• Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.

  Journal article

  Sharp Collaborative Group None., (2010), Am Heart J, 160, 785 - 794.e10

• Lipoprotein-associated phospholipase A₂ activity and mass in relation to vascular disease and nonvascular mortality.

  Journal article

  Heart Protection Study Collaborative Group None., (2010), J Intern Med, 268, 348 - 358

• Lipoprotein-associated phospholipase A(2) activity and mass in relation to vascular disease and nonvascular mortality

  Journal article

  Parish S. et al, (2010), JOURNAL OF INTERNAL MEDICINE, 268, 348 - 358

• Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.

  Journal article

  Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group None. et al, (2010), JAMA, 303, 2486 - 2494

• COMMON GENETIC VARIANTS ASSOCIATED WITH LOW Lp(a) KRINGLE-IV COPY NUMBER, HIGH Lp(a) CONCENTRATION, AND INCREASED RISK OF CORONARY HEART DISEASE

  Conference paper

  Seedorf U. et al, (2010), ATHEROSCLEROSIS SUPPLEMENTS, 11, 13 - 13

• Genetic variants associated with Lp(a) lipoprotein level and coronary disease.

  Journal article

  Clarke R. et al, (2009), N Engl J Med, 361, 2518 - 2528

• No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study

  Conference paper

  Hopewell JC. et al, (2009), CIRCULATION, 120, S606 - S606

• Common Genetic Variants Associated With Higher Lp(a) Concentrations and Increased Risk of Coronary Heart Disease

  Conference paper

  Clarke R. et al, (2009), CIRCULATION, 120, S589 - S589

• ASSOCIATION STUDY OF CORONARY ARTERY DISEASE (CAD) USING HUMANCVD 50K CHIP

  Conference paper

  Goel A. et al, (2009), ATHEROSCLEROSIS, 207, E4 - E4

• The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls.

  Journal article

  Parish S. et al, (2009), Eur Heart J, 30, 2137 - 2146

• Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.

  Journal article

  MRC/BHF Heart Protection Study Collaborative Group None. et al, (2009), BMC Clin Pharmacol, 9

• Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies.

  Journal article

  Prospective Studies Collaboration None. et al, (2009), Lancet, 373, 1083 - 1096

• Statin cost-effectiveness in the United States for people at different vascular risk levels.

  Journal article

  Heart Protection Study Collaborative Group None., (2009), Circ Cardiovasc Qual Outcomes, 2, 65 - 72

• Common variants at 30 loci contribute to polygenic dyslipidemia.

  Journal article

  Kathiresan S. et al, (2009), Nat Genet, 41, 56 - 65

• SLCO1B1 variants and statin-induced myopathy--a genomewide study.

  Journal article

  SEARCH Collaborative Group None. et al, (2008), N Engl J Med, 359, 789 - 799

• Empirical assessment of the validity of the 'fundamental theorem of the HapMap' in the light of 'cryptic' tagging of multiple susceptibility loci.

  Journal article

  Bochdanovits Z. et al, (2008), Eur J Hum Genet, 16, 525 - 529

• The exon 1-8C/G SNP in the PSMA6 gene contributes only a small amount to the burden of myocardial infarction in 6946 cases and 2720 controls from a United Kingdom population

  Journal article

  Bennett DA. et al, (2008), Eur.J.Hum.Genet., 16, 480 - 486

• Regarding "Does simvastatin save lives; If so, when and in whom?" - Reply

  Journal article

  Bulbulia R. et al, (2008), JOURNAL OF VASCULAR SURGERY, 47, 901 - 901

• Biomarkers of inflammation predict both vascular and non-vascular mortality in older men.

  Journal article

  Clarke R. et al, (2008), Eur Heart J, 29, 800 - 809

• Newly identified loci that influence lipid concentrations and risk of coronary artery disease.

  Journal article

  Willer CJ. et al, (2008), Nat Genet, 40, 161 - 169

• Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors.

  Journal article

  SEARCH Study Collaborative Group None. et al, (2007), Am Heart J, 154, 815 - 823.e6

• Cholesterol fractions and apolipoprotiens are strong predictors of heart disease mortality in older men

  Journal article

  Clarke R. et al, (2007), EUROPEAN HEART JOURNAL, 28, 87 - 87

• Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men.

  Journal article

  Clarke R. et al, (2007), Arch Intern Med, 167, 1373 - 1378

• MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS

  Conference paper

  Bulbulia R. et al, (2007), JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 49, 393A - 393A

• N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.

  Journal article

  Heart Protection Study Collaborative Group None. et al, (2007), J Am Coll Cardiol, 49, 311 - 319

• Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.

  Journal article

  Heart Protection Study Collaborative None. et al, (2006), BMJ, 333

• Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization'.

  Journal article

  Keavney B. et al, (2006), Int J Epidemiol, 35, 935 - 943

• Lymphotoxin-alpha gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study

  Journal article

  Clarke R. et al, (2006), PLoS.Genet., 2

• N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study

  Conference paper

  Emberson J. et al, (2005), CIRCULATION, 112, U867 - U867

• Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial

  Conference paper

  Mihaylova B. et al, (2005), CIRCULATION, 112, U900 - U901

• N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study

  Conference paper

  Emberson J. et al, (2005), EUROPEAN HEART JOURNAL, 26, 337 - 337

• Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.

  Journal article

  Mihaylova B. et al, (2005), Lancet, 365, 1779 - 1785

• The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393].

  Journal article

  Heart Protection Study Collaborative Group None., (2005), BMC Med, 3

• Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk.

  Journal article

  Keavney B. et al, (2004), Int J Epidemiol, 33, 1002 - 1013

• Effect of temperature and light on the stability of fat-soluble vitamins in whole blood over several days: implications for epidemiological studies.

  Journal article

  Clark S. et al, (2004), Int J Epidemiol, 33, 518 - 525

• New analyses of Heart Protection Study.

  Journal article

  Lemiengre M. et al, (2004), Lancet, 363, 1827 - 1828

• New analyses of Heart Protection Study - Reply

  Journal article

  Collins R. et al, (2004), LANCET, 363, 1828 - 1828

• Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.

  Journal article

  Collins R. et al, (2004), Lancet, 363, 757 - 767

• Economic evaluation of the Heart Protection Study

  Conference paper

  Briggs A. et al, (2003), CIRCULATION, 108, 776 - 776

• Comments on the MRC/BHF Heart Protection Study - Authors' reply

  Journal article

  Collins R. et al, (2003), LANCET, 362, 744 - 745

• MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

  Journal article

  Collins R. et al, (2003), Lancet, 361, 2005 - 2016

• In search of genetic precision.

  Journal article

  Humphries SE. et al, (2003), Lancet, 361, 1908 - 1909

• Heart Protection Study.

  Journal article

  Metcalfe RS. et al, (2003), Lancet, 361

• Heart Protection Study - Reply

  Journal article

  Collins R. et al, (2003), LANCET, 361, 529 - 530

• Large-scale evidence that the cardiotoxicity of smoking is not significantly modified by the apolipoprotein E ε2/ε3/ε4 genotype

  Journal article

  Keavney B. et al, (2003), Lancet, 361, 396 - 398

• Large-scale evidence that the cardiotoxicity of smoking is not significantly modified by the apolipoprotein E epsilon2/epsilon3/epsilon4 genotype.

  Journal article

  Keavney B. et al, (2003), Lancet, 361, 396 - 398

• Stability of plasma analytes after delayed separation of whole blood: implications for epidemiological studies.

  Journal article

  Clark S. et al, (2003), Int J Epidemiol, 32, 125 - 130

• MRC/BHF Heart Protection Study.

  Journal article

  Vaughan CJ. et al, (2002), Lancet, 360, 1780 - 1781

• MRC/BHF Heart Protection Study - Reply

  Journal article

  Collins R. et al, (2002), LANCET, 360, 1783 - 1784

• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  Journal article

  Heart Protection Study Collaborative Group None., (2002), Lancet, 360, 7 - 22

• MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial

  Journal article

  Collins R. et al, (2002), LANCET, 360, 23 - 33

• Randomized trial of cholesterol-lowering, and of antioxidant vitamins, in 6,000 people with diabetes mellitus

  Journal article

  Collins R. et al, (2002), JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 39, 245A - 245A

• Randomized trial of cholesterol-lowering and antioxidant vitamins in 7,000 high-risk individuals with LDL cholesterol below 120 mg/dl

  Journal article

  Collins R. et al, (2002), JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 39, 245A - 245A

• Randomized trial of cholesterol-lowering and antioxidant vitamins in 5,000 women at high-risk of coronary heart disease

  Journal article

  Collins R. et al, (2002), JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 39, 245A - 245A

• Effects of cholesterol-lowering therapy and antioxidant vitamin supplementation on the risk of stroke

  Journal article

  Collins R. et al, (2002), JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 39, 246A - 246A

• Plasma fibrinogen and fibrinogen genotypes in 4685 cases of myocardial infarction and in 6002 controls: Test of causality by "Mendelian randomisation"

  Journal article

  Youngman LD. et al, (2000), CIRCULATION, 102, 31 - 32

• Large-scale test of hypothesised associations between polymorphisms of lipid-related genes and myocardial infarction in about 5000 cases and 6000 controls

  Journal article

  Keavney BD. et al, (2000), CIRCULATION, 102, 852 - 852

• Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators.

  Journal article

  Keavney B. et al, (2000), Lancet, 355, 434 - 442

• Large-scale test of association between myocardial infarction, plasma lipid levels and apolipoprotein E e2/e3/e4 polymorphism in about 11,000 cases and controls

  Journal article

  Keavney B. et al, (2000), EUROPEAN HEART JOURNAL, 21, 249 - 249

• Large-scale test of hypothesised associations between the angiotensin-1 converting enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 5000 controls

  Journal article

  Keavney BD. et al, (1999), CIRCULATION, 100, 754 - 754

• Helicobacter pylori infection and early onset myocardial infarction: case-control and sibling pairs study.

  Journal article

  Danesh J. et al, (1999), BMJ, 319, 1157 - 1162

• MRC BHFHeart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience

  Journal article

  Meade T. et al, (1999), European Heart Journal, 20, 725 - 741

• Design, objectives, and lessons from a pilot 25 year follow up re-survey of survivors in the Whitehall study of London Civil Servants.

  Journal article

  Clarke R. et al, (1998), J Epidemiol Community Health, 52, 364 - 369

• ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

  Journal article

  Baigent C. et al, (1998), BMJ, 316, 1337 - 1343

• A comparison of the early outcome of acute myocardial infarction in women and men. The Third International Study of Infarct Survival Collaborative Group.

  Journal article

  Malacrida R. et al, (1998), N Engl J Med, 338, 8 - 14

• Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial

  Journal article

  Adib RS. et al, (1997), BRITISH JOURNAL OF UROLOGY, 79, 235 - 246

• Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Oxford Cholesterol Study Group.

  Journal article

  Keech AC. et al, (1996), Br J Clin Pharmacol, 42, 483 - 490

• Cigarette smoking, tar yields, and non-fatal myocardial infarction: 14,000 cases and 32,000 controls in the United Kingdom. The International Studies of Infarct Survival (ISIS) Collaborators.

  Journal article

  Parish S. et al, (1995), BMJ, 311, 471 - 477

• ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.

  Journal article

  (1995), Lancet, 345, 669 - 685

• RANDOMIZED CONTROLLED TRIAL OF ORAL CAPTOPRIL, OF ORAL ISOSORBIDE MONONITRATE AND OF INTRAVENOUS MAGNESIUM-SULFATE STARTED EARLY IN ACUTE MYOCARDIAL-INFARCTION - SAFETY AND HEMODYNAMIC-EFFECTS

  Journal article

  FLATHER M. et al, (1994), EUROPEAN HEART JOURNAL, 15, 608 - 619

• Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group.

  Journal article

  (1994), Lancet, 343, 311 - 322

• Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.

  Journal article

  Keech A. et al, (1994), Eur Heart J, 15, 255 - 269

• ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials.

  Journal article

  Collins R. et al, (1993), Am J Cardiol, 71, 1127 - 1130

• AFTER ISIS-3 - REPLY

  Journal article

  COLLINS R. et al, (1992), LANCET, 339, 1226 - 1227

• ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.

  Journal article

  (1992), Lancet, 339, 753 - 770

• Features affecting outcome during remission induction of acute myeloid leukaemia in 619 adult patients.

  Journal article

  Swirsky DM. et al, (1986), Br J Haematol, 64, 435 - 453

• The entry ECG in the early diagnosis and prognostic stratification of patients with suspected acute myocardial infarction.

  Journal article

  Yusuf S. et al, (1984), Eur Heart J, 5, 690 - 696

• Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction.

  Journal article

  Yusuf S. et al, (1983), Circulation, 67, I32 - I41

• REDUCTION IN INFARCT SIZE, MORBIDITY AND SHORT-TERM MORTALITY BY EARLY INTRAVENOUS BETABLOCKADE

  Journal article

  YUSUF S. et al, (1983), JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1, 676 - 676

• REDUCTION IN INFARCT SIZE, ARRHYTHMIAS AND CHEST PAIN BY EARLY INTRAVENOUS BETA-BLOCKADE IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION

  Journal article

  YUSUF S. et al, (1983), CIRCULATION, 67, 32 - 41

• CYTOLOGICAL FEATURES WITH PROGNOSTIC-SIGNIFICANCE IN AML

  Journal article

  SWIRSKY D. et al, (1983), BRITISH JOURNAL OF HAEMATOLOGY, 55, 189 - 190

• REDUCTION IN INFARCT SIZE, ARRHYTHMIAS, CHEST PAIN AND MORBIDITY BY EARLY INTRAVENOUS BETA-BLOCKADE IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION

  Journal article

  YUSUF S. et al, (1983), DRUGS, 25, 303 - 307

• REDUCTION IN INFARCT SIZE, ARRHYTHMIAS AND MORBIDITY BY EARLY INTRAVENOUS BETA BLOCKADE

  Journal article

  YUSUF S. et al, (1982), CLINICAL SCIENCE, 63, P2 - P2

• A phenome-wide association study of a lipoproteinassociated phospholipase A2 loss-of-function variant in 90 000 Chinese adults

  Journal article

  Millwood IY., International Journal of Epidemiology

• Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio

  Journal article

  Herrington W. et al, Clinical Journal of the American Society of Nephrology

• Burden of carotid artery atherosclerosis in Chinese adults: implications for future risk of cardiovascular diseases

  Journal article

  Clarke RJ. et al, European Journal of Preventive Cardiology

Recent Publications

• The Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin with Laropiprant on Health and Healthcare Costs

  Journal article

  Mihaylova BN. et al, (2016), Circulation: Cardiovascular Quality and Outcomes

• Lipoprotein-Associated Phospholipase A2 Loss-of-Function Variant and Risk of Vascular Diseases in 90,000 Chinese Adults.

  Journal article

  Millwood IY. et al, (2016), J Am Coll Cardiol, 67, 230 - 231

• Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation.

  Journal article

  Kato N. et al, (2015), Nat Genet, 47, 1282 - 1293

• Carotid artery stenosis, cardiovascular risk factors and ischaemic stroke in the China Kadoorie Biobank Study

  Conference paper

  Parish S. et al, (2015), EUROPEAN HEART JOURNAL, 36, 90 - 90

• Hypertension and age-specific burden of carotid atherosclerosis in China: results from 25,000 individuals in the China Kadoorie biobank study

  Conference paper

  Clarke R. et al, (2015), EUROPEAN HEART JOURNAL, 36, 993 - 993